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Background
Adoptive transfer of T cells transduced with tumor-
reactive Chimeric Antigen Receptors (CARs) is a pro-
mising strategy for cancer immunotherapy. The CD38
molecule, with its high and homogenous expression on
Multiple Myeloma (MM) cells, appears a suitable target
for antibody therapy. Prompted by this, we evaluated the
feasibility of targeting MM with CD38-CAR-transduced
(CD38-CAR) T cells.
Methods
We generated three retroviral CAR constructs based on
huCD38 antibodies, CD3ζ and 4-1BB signaling domains
and transduced them into T cells of healthy donors and
MM patients to test the in vitro and in vivo efficacy.
Results
Irrespective of the donor, CD38-CAR T cells lost CD38
expression, expanded readily and lysed MM and other
malignant cell lines in a cell dose-, and CD38-dependent
manner. They also lysed primary malignant cells from
acute myeloid leukemia, and multi-drug resistant MM
patients. Also in a xenotransplant model, i.v. injected
CD38-CAR T cells were effective against MM tumors
growing in a human bone marrow-like microenviron-
ment, thus demonstrating their ability to properly
migrate and infiltrate into the tumor niche to lyse
malignant cells. Although CD38-CAR T cells lysed
CD38+ monocytes, NK cells, CD34+ cells and to a lesser
extent CD38+ T and B cells, they did not hamper the
outgrowth progenitor cells into various myeloid lineages.
Furthermore, CD38-CART cells were controllable with a
caspase-9-based suicide gene.
Conclusions
These results signify the potential importance of CD38-
CAR T cells as therapeutic tools for CD38+ malignan-
cies, including MM, and warrant further safety and effi-
cacy evaluation in appropriate models.
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